Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CSBR
stocks logo

CSBR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q3
FY2026Q4
14.04M
+4.1%
0.000
-100%
16.43M
-3.6%
0.080
-75.76%
15.44M
+25%
0.050
-140.38%
Estimates Revision
The market is revising No Change the revenue expectations for Champions Oncology, Inc. (CSBR) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -10.82%.
Revenue Estimates for FY2026
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2026
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-10.82%
In Past 3 Month
Wall Street analysts forecast CSBR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CSBR is USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast CSBR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CSBR is USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.100
sliders
Low
12.00
Averages
High
12.00
Current: 6.100
sliders
Low
12.00
Averages
High
12.00
Craig-Hallum
Matt Hewitt
Strong Buy
Maintains
$8 → $12
2025-03-12
Reason
Craig-Hallum
Matt Hewitt
Price Target
$8 → $12
2025-03-12
Maintains
Strong Buy
Reason
Craig-Hallum analyst Matt Hewitt raised the firm's price target on Champions Oncology to $12 from $8 and keeps a Buy rating on the shares. The firm notes the company reported strong Q3 results, which featured a substantial data licensing deal signed by a large pharma company for rights to their cancer data. The company recognized $4.5M for this with potential of up to $8M. This deal led to revenues of $17M vs. $12.9M estimates and led to beats across the board. Craig-Hallum sees this company capitalizing on its large data offerings as it seeks to make drug development more efficient for customers.
Craig-Hallum
Matt Hewitt
Strong Buy
Maintains
$6 → $8
2024-12-12
Reason
Craig-Hallum
Matt Hewitt
Price Target
$6 → $8
2024-12-12
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Champions Oncology Inc (CSBR.O) is 40.67, compared to its 5-year average forward P/E of 41.19. For a more detailed relative valuation and DCF analysis to assess Champions Oncology Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
41.19
Current PE
40.67
Overvalued PE
90.31
Undervalued PE
-7.92

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
20.31
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
69.08
Undervalued EV/EBITDA
-28.47

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.85
Current PS
0.00
Overvalued PS
2.56
Undervalued PS
1.15
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CSBR News & Events

Events Timeline

(ET)
2025-07-18
08:33:03
Champions Oncology appoints Rob Brainin as CEO
select
2025-07-08 (ET)
2025-07-08
08:50:51
Champions Oncology announces launch of radiopharmaceutical services platform
select
2025-04-28 (ET)
2025-04-28
09:47:24
Champions Oncology obtains radioactive materials license
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
09-16Newsfilter
Transcript of Champions Oncology, Inc. (CSBR) Earnings Call for Q1 2026

  • Earnings Call Overview: Champions Oncology held its Q1 2026 earnings call on September 15, 2025, led by CEO Rob Brainin and CFO David Miller, discussing the company's financial performance and strategic direction.

  • Financial Performance: The company reported $14 million in revenue for Q1 2026, marking a recovery from previous quarter challenges, with growth primarily driven by its TOS business.

[object Object]
Preview
7.0
09-16SeekingAlpha
Champions Oncology aims for continuous revenue increase and improved margins as radiopharmaceuticals and data platforms progress.

  • Management Insights: CEO Rob Brainin highlighted a strong rebound in fiscal 2025 with record revenue of $14 million, driven by the TOS business and emerging data platform, while emphasizing the importance of strategic execution for long-term growth.

  • Financial Performance: The company reported a loss from operations of $0.5 million, with a gross margin decline to 43% due to increased outsourcing costs, but anticipates margin improvement as radiolabeling processes are internalized.

  • Outlook and Guidance: Management expects sequential revenue growth and margin expansion in Q2, maintaining a confident outlook despite challenges in the macro environment, particularly in biotech funding.

  • Analyst Sentiment: Analysts expressed cautious optimism regarding the data business and revenue growth, while management's tone remained confident, focusing on foundational strength and strategic continuity under the new CEO.

[object Object]
Preview
9.5
09-15SeekingAlpha
Champions Oncology Reports Non-GAAP EPS of $0.02, Exceeding Estimates by $0.03; Revenue of $14M Surpasses Expectations by $0.49M

  • Earnings Performance: Champions Oncology reported a Q1 Non-GAAP EPS of $0.02, exceeding expectations by $0.03.

  • Revenue Details: The company generated revenue of $14 million, reflecting a slight decline of 0.4% year-over-year, but still beating estimates by $0.49 million.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Champions Oncology Inc (CSBR) stock price today?

The current price of CSBR is 6.1 USD — it has increased 1.84 % in the last trading day.

arrow icon

What is Champions Oncology Inc (CSBR)'s business?

Champions Oncology, Inc. is a preclinical and clinical research services provider. The Company is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions. This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. It also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.

arrow icon

What is the price predicton of CSBR Stock?

Wall Street analysts forecast CSBR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CSBR is  USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Champions Oncology Inc (CSBR)'s revenue for the last quarter?

Champions Oncology Inc revenue for the last quarter amounts to 14.00M USD, decreased -0.47 % YoY.

arrow icon

What is Champions Oncology Inc (CSBR)'s earnings per share (EPS) for the last quarter?

Champions Oncology Inc. EPS for the last quarter amounts to -0.03 USD, decreased -133.33 % YoY.

arrow icon

What changes have occurred in the market's expectations for Champions Oncology Inc (CSBR)'s fundamentals?

The market is revising No Change the revenue expectations for Champions Oncology, Inc. (CSBR) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -10.82%.
arrow icon

How many employees does Champions Oncology Inc (CSBR). have?

Champions Oncology Inc (CSBR) has 213 emplpoyees as of December 05 2025.

arrow icon

What is Champions Oncology Inc (CSBR) market cap?

Today CSBR has the market capitalization of 82.59M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free